Invivyd Q1 net revenue $11.3M; net loss narrows to $16.3M; targets 1H 2025 profitability

Invivyd, Inc.

2025-Q1 EPS reported -$0.14 revenue$11,304,000

PEMGARDA net product revenue of $11.3M in Q1 2025, down from $13.8M in Q4 2024 due to sales force transition; re-acceleration seen in Q2 2025.
Net loss of $16.3M ($0.14 per share) vs $43.5M ($0.38) a year ago; R&D expenses fell to $10.6M from $31.2M.
Cash and equivalents $48.1M as of March 31 2025; secured $30M non-dilutive term loan facility with Silicon Valley Bank in April 2025.
FDA declined EUA expansion request for PEMGARDA as a treatment in Feb 2025 but provided potential near-term pathway for VYD2311.
VYD2311 Phase 1 data read-out (potency, half-life, safety) anticipated later in Q2 2025; pipeline expansion into RSV and measles underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.